Audentes therapeutics, inc. (BOLD)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Operating expenses:
Research and development

37,636

37,299

39,837

28,213

29,918

26,348

19,891

21,671

20,868

18,776

14,587

16,599

12,531

11,734

7,906

5,295

3,960

General and administrative

10,189

9,778

11,993

9,385

7,817

6,281

6,519

5,210

4,342

4,065

3,658

3,233

2,942

2,469

2,632

1,704

1,572

Total operating expenses

47,825

47,077

51,830

37,598

37,735

32,629

26,410

26,881

25,210

22,841

18,245

19,832

15,473

14,203

10,538

6,999

5,532

Loss from operations

-47,825

-47,077

-51,830

-37,598

-37,735

-32,629

-26,410

-26,881

-25,210

-22,841

-18,245

-19,832

-15,473

-14,203

-10,538

-6,999

-5,532

Interest income, net

2,112

2,353

2,472

2,368

1,509

1,294

859

284

221

115

147

167

116

92

97

54

63

Other expense, net

-28

-40

-33

-362

-65

-32

-20

-24

-20

-13

-17

-11

-12

-48

-23

-86

56

Net Income (Loss) Attributable to Parent

-45,741

-44,764

-49,391

-35,592

-36,291

-31,367

-25,571

-24,375

-25,009

-22,739

-18,115

-19,676

-15,369

-14,159

-10,464

-7,031

-5,413

Unrealized (losses) gains on investments, net

0

159

127

-

-4

51

-14

-

20

-8

-

-

-4

-1

14

15

-13

Comprehensive loss

-45,741

-44,605

-49,264

-35,685

-36,295

-31,316

-25,585

-24,438

-24,989

-22,747

-18,115

-19,704

-15,373

-14,160

-10,450

-7,016

-5,426

Net loss per share, basic and diluted (USD per share)

-1.00

-1.01

-1.13

-0.84

-0.97

-0.85

-0.74

-0.82

-0.88

-0.87

-0.83

6.63

-0.94

-6.43

-4.85

-5.48

-8.46

Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)

45,543

44,426

43,625

42,481

37,359

36,935

34,582

29,956

28,388

26,212

21,755

21,910

16,423

2,200

2,159

1,283

640